Tumor immunosuppressive factors

Tumor immunosuppressive factors refer to a wide array of soluble and cell-associated molecules, including cytokines (e.g., TGF-β, IL-10, VEGF), immune checkpoint ligands (e.g., PD-L1, Fas ligand), metabolic enzymes (e.g., indoleamine-2,3-dioxygenase, Arginase 1), and suppressive immune cell types (e.g., regulatory T cells, myeloid-derived suppressor cells), produced in the tumor microenvironment or by tumor cells. These factors act by inhibiting the proliferation and cytotoxicity of effector immune cells, blocking tumor antigen presentation, promoting the accumulation of additional suppressive cells, altering cellular metabolism, and thereby enabling tumor immune escape and resistance to immunotherapy. As a group, they represent a crucial barrier to effective cancer immunotherapy and a major reason for drug resistance and poor anti-tumor immune responses. However, "tumor immunosuppressive factors" is not a discrete, singular target but a descriptive term encompassing diverse mechanisms and should be elaborated into its individual molecular components for structured biomedical or drug discovery applications.

Other names

Tumor-derived immunosuppressive factorsTumor microenvironment immunosuppressive factorsImmunosuppressive cytokines (in context)Tumor immune evasion factors

Blockade of inhibitory ligand-receptor interactions (e.g., PD-1/PD-L1); Inhibition of immunosuppressive cytokine signaling (e.g., TGF-β pathway inhibitors); Inhibition of metabolic enzymes (e.g., IDO inhibitors restore T cell function by preventing tryptophan depletion).